Literature DB >> 10920382

Insights into the functions of type 1 (AT1) angiotensin II receptors provided by gene targeting.

L P Audoly1, M I Oliverio, T M Coffman.   

Abstract

The renin-angiotensin system (RAS) has a wide range of actions in biological processes ranging from development and reproduction to cardiovascular and renal functions. Most of these actions are mediated by the octapeptide hormone angiotensin II. The identified family of angiotensin II receptors is divided into two pharmacological classes: type 1 (AT1) and type 2 (AT2). The classically recognized actions of the RAS are primarily mediated by the AT1 subtype of angiotensin receptors, and these receptors are the targets of a new class of anti-hypertensive agents. In recent years, our understanding of the physiological functions of AT1 receptors has been advanced through the use of gene-targeting technology. In this review, we will summarize the emerging picture of AT1 receptor functions that has been provided by gene-targeting experiments.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10920382     DOI: 10.1016/s1043-2760(00)00279-4

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  9 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCIX. Angiotensin Receptors: Interpreters of Pathophysiological Angiotensinergic Stimuli [corrected].

Authors:  Sadashiva S Karnik; Hamiyet Unal; Jacqueline R Kemp; Kalyan C Tirupula; Satoru Eguchi; Patrick M L Vanderheyden; Walter G Thomas
Journal:  Pharmacol Rev       Date:  2015-10       Impact factor: 25.468

2.  Angiotensin-II type 1 receptor and NOX2 mediate TCF/LEF and CREB dependent WISP1 induction and cardiomyocyte hypertrophy.

Authors:  Prakashsrinivasan Shanmugam; Anthony J Valente; Sumanth D Prabhu; Balachandar Venkatesan; Tadashi Yoshida; Patrice Delafontaine; Bysani Chandrasekar
Journal:  J Mol Cell Cardiol       Date:  2011-03-02       Impact factor: 5.000

3.  Angiotensin-II mediates nonmuscle myosin II activation and expression and contributes to human keloid disease progression.

Authors:  Jennifer E Bond; Andrew Bergeron; Peter Thurlow; M Angelica Selim; Edith V Bowers; Anna Kuang; Howard Levinson
Journal:  Mol Med       Date:  2011-07-21       Impact factor: 6.354

4.  The angiotensin II type I receptor-associated protein, ATRAP, is a transmembrane protein and a modulator of angiotensin II signaling.

Authors:  Marco Lopez-Ilasaca; Xiushi Liu; Koichi Tamura; Victor J Dzau
Journal:  Mol Biol Cell       Date:  2003-09-05       Impact factor: 4.138

5.  Gain-of-function mutant of angiotensin II receptor, type 1A, causes hypertension and cardiovascular fibrosis in mice.

Authors:  Sandrine Billet; Sabine Bardin; Sonia Verp; Véronique Baudrie; Annie Michaud; Sophie Conchon; Martine Muffat-Joly; Brigitte Escoubet; Evelyne Souil; Ghislaine Hamard; Kenneth E Bernstein; Jean Marie Gasc; Jean-Luc Elghozi; Pierre Corvol; Eric Clauser
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

6.  Epigenetic modification of the renin-angiotensin system in the fetal programming of hypertension.

Authors:  Irina Bogdarina; Simon Welham; Peter J King; Shamus P Burns; Adrian J L Clark
Journal:  Circ Res       Date:  2007-01-25       Impact factor: 17.367

7.  Chemical Composition and Hypotensive Effect of Campomanesia xanthocarpa.

Authors:  Liane Santariano Sant'Anna; Liara Merlugo; Catrine Santos Ehle; Jessica Limberger; Maquelen Blanco Fernandes; Marí Castro Santos; Andreas Sebastian Loureiro Mendez; Fávero Reisdorfer Paula; Cleci Menezes Moreira
Journal:  Evid Based Complement Alternat Med       Date:  2017-05-11       Impact factor: 2.629

8.  Stem Cells in Keloid Lesions: A Review.

Authors:  Kim H Lim; Tinte Itinteang; Paul F Davis; Swee T Tan
Journal:  Plast Reconstr Surg Glob Open       Date:  2019-05-16

9.  Characterization of the angiotensin (AT1b) receptor promoter and its regulation by glucocorticoids.

Authors:  Irina G Bogdarina; Peter J King; Adrian J L Clark
Journal:  J Mol Endocrinol       Date:  2009-05-01       Impact factor: 5.098

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.